Find clinical trials and studies for type 1 diabetes

What’s involved?

Participants receive an injection of tirzepatide or placebo once a week for 6 weeks, and will complete tests measuring the treatment’s effect on insulin resistance, food digestion and the body’s ability to generate a glucagon response to a low blood glucose level.

What are the benefits of taking part?

Participants may benefit from learning more about their metabolism, insulin sensitivity, and hormone responses during the study. While direct health benefits cannot be guaranteed, taking part may help improve researchers’ understanding of adjunct therapies in T1D, which are drugs designed to be taken in addition to insulin.

Participants will be reimbursed for their time and travel associated with attending study visits.

Ethics approval number

The study has received ethical approval (reference number: 2025/ETH01619).

Want to take part?

If you have any questions or are keen to participate, please contact the study team on [email protected] or 0491 731 769.

What’s involved? 

Participants will receive either teplizumab or placebo (a nonactive substance that looks like teplizumab) in increasing doses through a tube in the arm (known as an intravenous infusion). This will take place twice throughout the study over 2 x 12-day periods, 6 months apart. The study will last approximately 84 weeks (18 months) and includes 32 study site visits for blood tests, physical exams, and questionnaires. Participants will wear a continuous glucose monitor (CGM) periodically and will keep a diary of insulin use and any hypos or hypos they experience. They will continue their usual diabetes care throughout the study. 

What are the benefits of taking part? 

Given the experimental nature of the study, it is not certain that you will directly benefit from participating. Only 1/3 of people taking part will receive a placebo, with the other 2/3 getting teplizumab, meaning you are more likely to receive the drug.

There is evidence that adding teplizumab to insulin treatment can reduce the destruction of insulin-making cells. It is hoped that treatment with teplizumab will help your body continue to make insulin. Your blood glucose may improve (e.g. a lower average glucose level or less fluctuation in glucose levels), and the study doctor might consider recommending lower doses of insulin. You may experience an overall improved quality of life or decreased overall feelings of stress from difficulty managing T1D.

The research team will follow your health closely. You will receive regular medical check-ups by a team experienced in T1D, providing detailed insights into your health.

Ethics approval number 

The study is officially registered here.

Want to take part? 

Contact the following people depending on your location:

South Australia:
Kirsty Herewane on 0435991434 / [email protected]
Alison Gwiazdzinski on 0417871278 / [email protected]

Queensland:
Ali Cook or A/Prof Tony Huynh on 0487 062 275 / [email protected]

Western Australia:
Charly Keough on 0427 933 664 / [email protected]

To participate in TRACE-T1D you need to be referred by the doctor looking after your child/teenager. After you’ve been referred, you’ll be contacted by a member of the TRACE-T1D team who will:

• Phone you to provide more information about the study.
• Email or post you the participant information sheet and make an appointment where you can ask for more details or any questions you have about the study.
• If you wish to participate, you will be asked to confirm that you understand the information provided and, if applicable, that you have the authority to provide consent for the participant.
• Study equipment will be sent to you via registered post for you to insert on you/r child/teenager at home.
• You will be asked to return the study equipment back to the TRACE-T1D team via a pre-paid satchel.
• The study team will provide the data collected from the CGM wear period to your referring doctor, who will then discuss these results with you and advise when to have your next CGM session.

For more details 

Please send an email to [email protected].

Learn more about this study, which is funded by Breakthrough T1D.

What’s involved?

In this study 2 out of every 3 people will receive baricitinib and 1 out of every 3 people will receive a placebo.

Baricitinib (and the study placebo) is taken in tablet form or as a liquid for those who cannot swallow tablets.

To monitor your health closely, you’ll need to attend the clinic approximately 10 times over 14 months. At each visit the study team will monitor your blood glucose levels, insulin production and overall health to ensure you’re well and that the study treatment is safe and effective.

What are the benefits? 

Although there’s no guarantee the treatment will be effective, it may help protect insulin-producing cells and preserve the body’s natural insulin production. Participants will receive regular medical check-ups from diabetes specialists.

Participants may be able to receive reimbursement for travel expenses. Please discuss this with the trial staff.

Want to know more?

For more details, contact the team at ATIC or visit their website. 

Contact the ATIC team

What’s involved?

Participants will take a daily tablet of either baricitinib or placebo for at least 117 weeks (2 years and 3 months). If you’re unable to swallow tablets, you can take the medication as liquid.

The BARICADE studies are testing whether a drug called baricitinib, which is already used to treat other autoimmune conditions, can delay the progression of T1D. In a landmark trial in 2023, Australian researchers showed baricitinib can help preserve insulin production and stabilise blood glucose levels in people newly diagnosed with T1D.

T1D develops in stages: people in stage 1 or 2 (early-stage) T1D have biological markers of T1D but don’t yet need to take insulin, while people in stage 3 T1D experience symptoms and need insulin therapy. BARICADE-DELAY will test whether baricitinib can delay progression to stage 3 T1D in people who currently have early-stage T1D.

What are the benefits of taking part?

In this study, 2/3 participants will receive baricitinib and 1/3 will receive a placebo, meaning there is more chance you will receive the drug, which has been shown to preserve insulin production. Researchers hope people taking baricitinib in this study will get more time in the early stages of T1D without needing to take insulin.

Taking part will give you regular health checks and access to diabetes specialists. Participants may be able to receive reimbursement for travel expenses.

Want to know more?

For more details, contact the team at ATIC or visit their website. 

Contact the ATIC team

What’s involved?  

The TZP-T1D 2.0 study will last 28 weeks and participants will be randomly put into 2 groups. 

First, Group A will give themselves tirzepatide as a once-weekly injection alongside their usual insulin treatment for 28 weeks, while Group B follows their usual insulin regimen without taking tirzepatide. Then, after a 4-week period where neither group receives tirzepatide, the groups will swap so Group B receives tirzepatide for 28 weeks and Group A does not. The researchers will monitor participants from both groups for another 3 months. 

The dose of tirzepatide the participants give themselves will increase every 4 weeks, providing participants don’t experience any negative side effects from taking it.  

What are the benefits of taking part?  

Everyone who takes part in the TZP-T1D 2.0 study gets to take tirzepatide in a safe and controlled way during the study, with specialist support from the research team. 

Ethics approval number  

This study has been approved by Northern Sydney Local Health District Human Research Ethics Committee and the ethics approval number is 2024/ETH02430. 

How to take part

For more information and to take part, email Dr Matilda Longfield ([email protected]) or Sarah Glastras ([email protected]). 

What’s involved? 

Participation in the study involves 6 face-to-face visits at the Princess Alexandra Hospital in Brisbane, Queensland. During the visits, the researchers will give participants either ASITI or a non-active placebo, take blood samples and do a 2-hour mixed meal tolerance test. 

What are the benefits of taking part? 

The researchers are particularly keen to involve people from rural Queensland, with funding available for participants to travel to recruitment centres and clinic visits. The drug could help protect insulin-making beta cells, but the researchers do not know who is taking the active drug and how effective it is, so they can’t guarantee direct health benefits from taking part. However, taking part will help them learn whether ASITI-201 is a potential treatment for T1D, which could benefit other people with T1D in the future. 

Ethics approval number 

This study has been approved by the Metro South Human Research Ethics Committee, reference number: HREC/2024/QMS/107946. 

Want to take part? 

For more information and to sign up, please email: [email protected] 

What’s involved?

Participants will visit a clinic 15 times over 6 months.

First, you will have a 2-hour long screening visit, which involves a physical examination and blood tests to check whether you are eligible to take part. If you are eligible to join, you will be asked to return to the clinic within 60 days to have a meal test and receive the first dose of MTX-101 through a vein in your arm. This visit will last around 8 hours.

Over the next 3 weeks, you will have 3 short clinic visits to complete further blood samples and health checks.

A month after the first dose of MTX-101, you will receive your second dose. You will then be monitored over the next few months, which involves more meal tests, blood tests and health checks.

What are the benefits of participating?

Everyone who takes part will receive 2 doses of MTX-101. Studies in animals have shown this drug can prevent the immune system’s attack on insulin-making cells. Early results from the first few participants in this clinical trial suggest it can help people with T1D make more of their own insulin for longer.

However, there is no guarantee you will receive any direct benefits from the drug.

Regardless of the effectiveness of the drug, you will be contributing valuable scientific knowledge that may lead to new treatments for T1D.

Participants in this trial will be compensated for their time and travel expenses.

Want to know more?

For more details, contact the team at ATIC or visit their website. 

Contact the ATIC team

Ethics approval number 

This study has been approved by St Vincent’s Hospital Melbourne, reference number: HREC137/25. 

What’s involved?  

Participants will be given either SAB-142 or a non-active placebo twice over 2 days; once at the beginning of the study and once after 6 months.

The treatment will be given slowly through a vein in the arm over 4 to 6 hours per day. Participants will also attend 5 in-person clinic visits and 3 phone check-ins throughout the year. At each visit, the team will monitor participants’ blood glucose levels, insulin production, and overall health to ensure the treatment is safe and effective. 

What are the benefits of participating?  

Although there is no guarantee that the treatment will be effective, it may help protect insulin-producing cells and preserve natural insulin production. Participants receive regular medical check-ups from diabetes specialists.

Participants will also be compensated for their time/travel. 

Ethics approval number: St Vincent’s HREC Ref: HREC 219/25 

What’s involved? 

This study lasts 27-30 months, which is around 2 years, and involves long-term follow-up, regular monitoring, and a combination of clinic visits and remote check-ins during this period. It includes a screening period followed by two treatment phases (Year 1 and Year 2).  

Participants will attend at least 20 study visits, including a mix of in-person visits (at least 7) and remote appointments (via phone or video). Early in the study, participants complete screening assessments and a specialised clamp test. Participants are grouped based on their current experience with automated insulin delivery (AID) systems.  

In Year 1, participants are randomly assigned to different treatment approaches. Depending on the group, this may include starting or continuing using AID or receiving an educational program (MyHypoCompass) to improve recognition and management of low blood glucose (hypoglycaemia). 

In Year 2, participants continue to be monitored, with their treatment and hypoglycaemia awareness reviewed. Some may remain on their initial treatment, while others may be reassigned to an additional intervention (HARPdoc) or transition to using AID. 

What are the benefits of taking part? 

$1,871.25. 

Want to take part? 

Fill out the form on the Diabetes Technology Research Group Melbourne website to get involved.

Contact: [email protected] 

What’s involved? 

The whole study lasts around 6 months, starting with a screening visit lasting up to 2 hours and a 1-hour training session. This is followed by a randomisation visit lasting up to 3 hours in which participants are randomly assigned to a group, provide a blood sample, complete questionnaires, and receive their technology. 

Then the treatment period of the clinical trials begins and lasts for 24 weeks. During the treatment period, participants will have 13 in person and online clinic appointments including 30-minute weekly remote reviews at first and several in-person visits lasting 1–2 hours. The appointments involve doing blood tests, questionnaires, and wearing a movement monitor (actigraph) for short periods. 

At the final visit, participants complete assessments, return study devices, and provide a final blood sample. Those using Omnipod 5 will also take part in a user experience interview.  

What are the benefits of taking part? 

People who complete all study activities will receive $400 compensation for their time and effort. Those in the Omnipod 5 study group will also get to use this insulin pump free of charge for a 24-week period. People who were assigned to the usual care group, will have the offer to try the Omnipod 5 for 3 months after finishing the study. 

Ethics approval number 

This study has received ethical approval from the St Vincent’s Hospital Melbourne (Public) Human Research Ethics Committee reference: 129/25. 

Want to take part? 

Fill out the form on the Diabetes Technology Research Group Melbourne website to get involved.

Contact: [email protected]  

What’s involved? 

Taking part in this study lasts for up to 6 months, which involves attending a minimum of 10 clinic visits (1 initial visit, 8 supervised exercise sessions, 1 final visit), along with additional remote activities from home.  

The study begins with a screening visit to see if you are eligible to take part, which lasts up to 3 hours and involves medical assessments, blood tests, and an exercise test. Eligible participants will then start using the first study device, NMX7-AID. There is a 4-week run-in period at home, with remote monitoring and regular check-ins.  

The main study includes 8 2-hour exercise sessions at the clinic, where participants complete monitored exercise, provide blood samples, and receive clinical assessments. Between sessions, participants will upload device data, change sensors, and complete preparation activities at home, with regular remote support. 

Midway through the study, participants switch from NMX7-AID to NMX8-AID system and complete another 4-week run-in period, along with a free-living phase and use of a fitness tracker. 

At the final study visit (which lasts up to 2 hours) participants return their study devices and complete a feedback interview about their experience. 

What are the benefits of taking part? 

You will be reimbursed a maximum of $900 in total if you complete all study activities. Taking part also gives you the opportunity to try 2 pieces of new technology with support from diabetes technology experts. 

Ethics approval number  

This study has received ethical approval from the St Vincent’s Hospital Melbourne (Public) Human Research Ethics Committee ref# 263/25. 

Want to take part? 

Fill out the form on the Diabetes Technology Research Group Melbourne website to get involved.

Contact: [email protected] 

What’s involved? 

Participation involves completing a short online survey about your journey from first symptoms to diagnosis. The survey is anonymous and takes around 20 minutes to complete. You then have the option to have a 30-45 minute follow-up interview online to share more details about your experience.   

What are the benefits of taking part? 

Taking part in this study has no direct benefit but you would be contributing to improving diagnosis and care for people in a similar situation to you. 

Ethics approval number 

Approved by St Vincent’s Human Research Ethics Committee (HREC) [ETH02403]. 

Want to take part? 

Register your interest here and a member of the study team will contact you. 

If you have any questions or are keen to participate, please email Merton Cheng on [email protected]. 

What’s involved? 

Your participation will involve completing a survey, which should take approximately 10 minutes. A small number of participants will additionally be offered the opportunity to be interviewed online via Microsoft Teams or Zoom, depending on your preference. Interviews are expected to take up to 60 minutes and can be scheduled at a time that suits you. 

What are the benefits of taking part? 

Whilst there will be no direct benefit to you for participating in this project, findings from this project will help inform future recommendations to better support young adults with chronic health conditions, including T1D. 

Ethics approval number and contact

The study has received ethical approval from The University of Queensland Human Research Ethics Committee (2026/HEO10607). 

If you have any questions, please email Dr Lisa Gardener at [email protected]  

Want to take part? 

Complete the survey here.

What’s involved? 

The MIND-MAP study is looking for adults affected by diabetes to reflect on their journey with diabetes and share their experiences about their emotional wellbeing. This information will be captured yearly through 4 short online surveys. Each survey takes around 20 minutes and can be done on a computer, tablet, or phone. 

What are the benefits of taking part? 

Complete all surveys and enter the draw to win 1 of 20 $100 e‑gift cards. 

Ethics approval number 

HREC Committee Name: Deakin University Human Research Ethics Committee. Approval Number: 2024/HE000401 

Want to take part? 

Complete the survey here.

You can also learn more about the study.

Contact: [email protected]

What’s involved?

Participants will complete an anonymous online questionnaire containing 25 questions. It should only take 5–15 minutes to complete, but this may vary depending on your responses.

You will be asked questions about:

• your background and connection to T1D
• your experiences related to exercise and glucose management
• any challenges and support needs you have relating to exercise
• your opinions about potential chatbot features.

What are the benefits of taking part?

There are no direct personal benefits from participating in this study. But your responses will help guide the development of safer and more useful digital health tools to help people with T1D to exercise safely and manage their blood glucose more easily alongside exercise.

Ethics approval number

This study has been approved by the University of Melbourne Human Research Ethics Committee, reference number: 2026-35355-78635-3.

Have questions?

Contact the lead researcher if you have any questions: [email protected]

What’s involved?  

Part 1: A 15-minute online survey about your / your child’s experiences receiving healthcare for your / their chronic illness. 

Part 2 (optional): A one-hour online interview or focus group to explore these experiences in more depth. 

What are the benefits of participating?  

You will be providing insights that could contribute to improving healthcare for young people living with chronic illnesses. 

Ethics approval number  

Participation is voluntary, and all contributions are anonymous. The study has received human research ethics approval (2024/ETH02468).

How to take part 

To take part, click the link below and enter the code P3DRPTFNL.

To learn more, contact Dr Nghi Bui; email [email protected].

What’s involved?  

Participants will complete an online survey, which will take roughly 10 minutes. You then have the option to join the research team for an in-person workshop at the NICM Health Research Institute involving activities that explore what, how and why you might use nutritional supplements and complementary medicine to manage your T1D condition and decide if the supplements are ‘safe’ or ‘effective’. 

What are the benefits of participating?  

By taking part, you would be helping researchers learn more about how complementary medicines may be used to help people with T1D. There is also an opportunity for you to participate in a draw or meet the researchers and other young people with T1D at a face-to-face workshop. 

Ethics approval number  

This study has been approved by the Western Sydney University Ethics Committee, reference number H16767 

Want to take part?  

Complete the survey here.

What are the benefits of participating?

Testing through Type1Screen can identify the early stages of T1D. Detecting T1D early, before symptoms develop, combined with monitoring, can lead to better long-term health for those with the condition. For example, it can decrease the risk of developing the dangerous condition diabetic ketoacidosis (DKA). It can also prepare families for a T1D diagnosis.

Those who test positive for early-stage T1D will be connected to their closest diabetes centre and offered the opportunity to enrol in trials of new therapies that can potentially slow or stop the progression of the condition.

Want to know more? 

For more information, contact the team by phoning (03) 9342 7063

What is involved?

You will complete an online, anonymous questionnaire which is expected to take 20-30 minutes. You can complete it in one sitting or return to the survey.

What are the benefits of participating?

This study will help update guidelines for physical activity in T1D and provide education for people with T1D and clinicians, helping them make more informed choices to manage the condition.

We would like to talk to people who have consented to an implanted active medical device for the management of their diabetes, or have consented to such a device on behalf of another person. The types of implants we are interested in are those that are medically implanted into the user and rely on wireless or Bluetooth connectivity to communicate patient information, such as blood glucose monitors (either connected to an insulin pump or not) that transmit information or data from the implant to an external source (such as the clinical team, the manufacturer or an external app on your phone or computer).

We want to talk with people about their experiences in providing consent to explore whether the existing laws about this topic are sufficient in ensuring informed consent for the collection, storage and future use of the data that is sent and received from those devices.

Interviews will be undertaken using Microsoft Teams, so participants can be located anywhere in Australia.